bioAffinity Technologies

BIAF

Market cap $15.3M

SAN ANTONIO, Texas--(BUSINESS WIRE)-- #AI--The US Patent and Trademark Office will issue BIAF a new patent on its flow cytometry+AI platform that detects lung cancer as early as Stage 1A.

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies received written notice from Nasdaq stating that the Company has regained compliance with continued listing requirements.

JERSEY CITY, N.J. , Oct. 9, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has closed the previously announced definitive agreements for the purchase and sale of 720,000 shares of common stock at a purchase price of $2.50 per share in a registered direct offering priced at-the-market under Nasdaq rules.

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies closed on a $1.8 million registered direct offering of common stock.

JERSEY CITY, N.J. , Oct. 8, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has entered into definitive agreements for the purchase and sale of 720,000 shares of common stock, par value $0.007 per share, at a purchase price of $2.50  per share in a registered direct offering priced at-the-market under Nasdaq rules.

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces a $1.8 million registered direct offering of common stock.

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Sales of bioAffinity's CyPath® Lung test for lung cancer reached a new high in Q3 2025, representing a 95% increase over the previous quarter.

JERSEY CITY, N.J. , Sept. 30, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer has closed its previously announced public offering of securities as described below for aggregate gross proceeds to the Company of $4.8 million, before deducting agent fees and other estimated expenses payable by the company.

SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies closes $4.8 million public offering.

JERSEY CITY, N.J. , Sept. 29, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer has priced a public offering of securities as described below for aggregate gross proceeds to the Company of $ million, before deducting agent fees and other estimated expenses payable by the company.